Industry: Machinery & Equipment
Published Date: 2025-02-25
Pages: 140 Pages
Report ld: 4240100
Request Sample
Customized Report
The global market for PRRS Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
North American market for PRRS Vaccines was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PRRS Vaccines was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for PRRS Vaccines was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key companies of PRRS Vaccines include CAHIC, Merial, MSD Animal Health, Chopper Biology, Ceva, ChengDu Tecbond, Veterinary, Ringpu Biology, Qilu Animal, DHN, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for PRRS Vaccines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of PRRS Vaccines by region & country, by Type, and by Application.
The PRRS Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PRRS Vaccines.
MARKET SEGMENTATION
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PRRS Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of PRRS Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of PRRS Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 PRRS Vaccines Product Introduction
1.2 Global PRRS Vaccines Market Size Forecast
1.2.1 Global PRRS Vaccines Sales Value (2020-2031)
1.2.2 Global PRRS Vaccines Sales Volume (2020-2031)
1.2.3 Global PRRS Vaccines Sales Price (2020-2031)
1.3 PRRS Vaccines Market Trends & Drivers
1.3.1 PRRS Vaccines Industry Trends
1.3.2 PRRS Vaccines Market Drivers & Opportunity
1.3.3 PRRS Vaccines Market Challenges
1.3.4 PRRS Vaccines Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global PRRS Vaccines Players Revenue Ranking (2024)
2.2 Global PRRS Vaccines Revenue by Company (2020-2025)
2.3 Global PRRS Vaccines Players Sales Volume Ranking (2024)
2.4 Global PRRS Vaccines Sales Volume by Company Players (2020-2025)
2.5 Global PRRS Vaccines Average Price by Company (2020-2025)
2.6 Key Manufacturers PRRS Vaccines Manufacturing Base and Headquarters
2.7 Key Manufacturers PRRS Vaccines Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of PRRS Vaccines
2.9 PRRS Vaccines Market Competitive Analysis
2.9.1 PRRS Vaccines Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by PRRS Vaccines Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PRRS Vaccines as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Live Vaccines
3.1.2 Killed Vaccines
3.2 Global PRRS Vaccines Sales Value by Type
3.2.1 Global PRRS Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global PRRS Vaccines Sales Value, by Type (2020-2031)
3.2.3 Global PRRS Vaccines Sales Value, by Type (%) (2020-2031)
3.3 Global PRRS Vaccines Sales Volume by Type
3.3.1 Global PRRS Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global PRRS Vaccines Sales Volume, by Type (2020-2031)
3.3.3 Global PRRS Vaccines Sales Volume, by Type (%) (2020-2031)
3.4 Global PRRS Vaccines Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Government Tender
4.1.2 Market Sales
4.2 Global PRRS Vaccines Sales Value by Application
4.2.1 Global PRRS Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global PRRS Vaccines Sales Value, by Application (2020-2031)
4.2.3 Global PRRS Vaccines Sales Value, by Application (%) (2020-2031)
4.3 Global PRRS Vaccines Sales Volume by Application
4.3.1 Global PRRS Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global PRRS Vaccines Sales Volume, by Application (2020-2031)
4.3.3 Global PRRS Vaccines Sales Volume, by Application (%) (2020-2031)
4.4 Global PRRS Vaccines Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global PRRS Vaccines Sales Value by Region
5.1.1 Global PRRS Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global PRRS Vaccines Sales Value by Region (2020-2025)
5.1.3 Global PRRS Vaccines Sales Value by Region (2026-2031)
5.1.4 Global PRRS Vaccines Sales Value by Region (%), (2020-2031)
5.2 Global PRRS Vaccines Sales Volume by Region
5.2.1 Global PRRS Vaccines Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global PRRS Vaccines Sales Volume by Region (2020-2025)
5.2.3 Global PRRS Vaccines Sales Volume by Region (2026-2031)
5.2.4 Global PRRS Vaccines Sales Volume by Region (%), (2020-2031)
5.3 Global PRRS Vaccines Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America PRRS Vaccines Sales Value, 2020-2031
5.4.2 North America PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe PRRS Vaccines Sales Value, 2020-2031
5.5.2 Europe PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific PRRS Vaccines Sales Value, 2020-2031
5.6.2 Asia Pacific PRRS Vaccines Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America PRRS Vaccines Sales Value, 2020-2031
5.7.2 South America PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa PRRS Vaccines Sales Value, 2020-2031
5.8.2 Middle East & Africa PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions PRRS Vaccines Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions PRRS Vaccines Sales Value
6.2.1 Key Countries/Regions PRRS Vaccines Sales Value, 2020-2031
6.2.2 Key Countries/Regions PRRS Vaccines Sales Volume, 2020-2031
6.3 United States
6.3.1 United States PRRS Vaccines Sales Value, 2020-2031
6.3.2 United States PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.3.3 United States PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe PRRS Vaccines Sales Value, 2020-2031
6.4.2 Europe PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China PRRS Vaccines Sales Value, 2020-2031
6.5.2 China PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.5.3 China PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan PRRS Vaccines Sales Value, 2020-2031
6.6.2 Japan PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea PRRS Vaccines Sales Value, 2020-2031
6.7.2 South Korea PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia PRRS Vaccines Sales Value, 2020-2031
6.8.2 Southeast Asia PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India PRRS Vaccines Sales Value, 2020-2031
6.9.2 India PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.9.3 India PRRS Vaccines Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 CAHIC
7.1.1 CAHIC Company Information
7.1.2 CAHIC Introduction and Business Overview
7.1.3 CAHIC PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 CAHIC PRRS Vaccines Product Offerings
7.1.5 CAHIC Recent Development
7.2 Merial
7.2.1 Merial Company Information
7.2.2 Merial Introduction and Business Overview
7.2.3 Merial PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Merial PRRS Vaccines Product Offerings
7.2.5 Merial Recent Development
7.3 MSD Animal Health
7.3.1 MSD Animal Health Company Information
7.3.2 MSD Animal Health Introduction and Business Overview
7.3.3 MSD Animal Health PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 MSD Animal Health PRRS Vaccines Product Offerings
7.3.5 MSD Animal Health Recent Development
7.4 Chopper Biology
7.4.1 Chopper Biology Company Information
7.4.2 Chopper Biology Introduction and Business Overview
7.4.3 Chopper Biology PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Chopper Biology PRRS Vaccines Product Offerings
7.4.5 Chopper Biology Recent Development
7.5 Ceva
7.5.1 Ceva Company Information
7.5.2 Ceva Introduction and Business Overview
7.5.3 Ceva PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Ceva PRRS Vaccines Product Offerings
7.5.5 Ceva Recent Development
7.6 ChengDu Tecbond
7.6.1 ChengDu Tecbond Company Information
7.6.2 ChengDu Tecbond Introduction and Business Overview
7.6.3 ChengDu Tecbond PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 ChengDu Tecbond PRRS Vaccines Product Offerings
7.6.5 ChengDu Tecbond Recent Development
7.7 Veterinary
7.7.1 Veterinary Company Information
7.7.2 Veterinary Introduction and Business Overview
7.7.3 Veterinary PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Veterinary PRRS Vaccines Product Offerings
7.7.5 Veterinary Recent Development
7.8 Ringpu Biology
7.8.1 Ringpu Biology Company Information
7.8.2 Ringpu Biology Introduction and Business Overview
7.8.3 Ringpu Biology PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Ringpu Biology PRRS Vaccines Product Offerings
7.8.5 Ringpu Biology Recent Development
7.9 Qilu Animal
7.9.1 Qilu Animal Company Information
7.9.2 Qilu Animal Introduction and Business Overview
7.9.3 Qilu Animal PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Qilu Animal PRRS Vaccines Product Offerings
7.9.5 Qilu Animal Recent Development
7.10 DHN
7.10.1 DHN Company Information
7.10.2 DHN Introduction and Business Overview
7.10.3 DHN PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 DHN PRRS Vaccines Product Offerings
7.10.5 DHN Recent Development
7.11 CAVAC
7.11.1 CAVAC Company Information
7.11.2 CAVAC Introduction and Business Overview
7.11.3 CAVAC PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 CAVAC PRRS Vaccines Product Offerings
7.11.5 CAVAC Recent Development
7.12 Komipharm
7.12.1 Komipharm Company Information
7.12.2 Komipharm Introduction and Business Overview
7.12.3 Komipharm PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Komipharm PRRS Vaccines Product Offerings
7.12.5 Komipharm Recent Development
7.13 Agrovet
7.13.1 Agrovet Company Information
7.13.2 Agrovet Introduction and Business Overview
7.13.3 Agrovet PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Agrovet PRRS Vaccines Product Offerings
7.13.5 Agrovet Recent Development
7.14 Bioveta
7.14.1 Bioveta Company Information
7.14.2 Bioveta Introduction and Business Overview
7.14.3 Bioveta PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Bioveta PRRS Vaccines Product Offerings
7.14.5 Bioveta Recent Development
7.15 Jinyu Bio-Technology
7.15.1 Jinyu Bio-Technology Company Information
7.15.2 Jinyu Bio-Technology Introduction and Business Overview
7.15.3 Jinyu Bio-Technology PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Jinyu Bio-Technology PRRS Vaccines Product Offerings
7.15.5 Jinyu Bio-Technology Recent Development
7.16 Institutul Pasteur
7.16.1 Institutul Pasteur Company Information
7.16.2 Institutul Pasteur Introduction and Business Overview
7.16.3 Institutul Pasteur PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.16.4 Institutul Pasteur PRRS Vaccines Product Offerings
7.16.5 Institutul Pasteur Recent Development
7.17 MVP
7.17.1 MVP Company Information
7.17.2 MVP Introduction and Business Overview
7.17.3 MVP PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.17.4 MVP PRRS Vaccines Product Offerings
7.17.5 MVP Recent Development
7.18 Tecon
7.18.1 Tecon Company Information
7.18.2 Tecon Introduction and Business Overview
7.18.3 Tecon PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.18.4 Tecon PRRS Vaccines Product Offerings
7.18.5 Tecon Recent Development
7.19 Zoetis
7.19.1 Zoetis Company Information
7.19.2 Zoetis Introduction and Business Overview
7.19.3 Zoetis PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.19.4 Zoetis PRRS Vaccines Product Offerings
7.19.5 Zoetis Recent Development
8 Industry Chain Analysis
8.1 PRRS Vaccines Industrial Chain
8.2 PRRS Vaccines Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 PRRS Vaccines Sales Model
8.5.2 Sales Channel
8.5.3 PRRS Vaccines Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
The global PRRS Vaccines market size was US$ 429 million in 2025 and is forecast to reach a readjusted size of US$ 543 million by 2032 with a CAGR of 3.5% during the forecast period 2026-2032.
Published Date: 2026-03-09
Pages: 104
USD 4250.00
(Single User License)
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 543 million by 2032, at a CAGR of 3.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-09
Pages: 179
USD 4900.00
(Single User License)
The global market for PRRS Vaccines was estimated to be worth US$ 429 million in 2025 and is projected to reach US$ 543 million, growing at a CAGR of 3.5% from 2026 to 2032.
Published Date: 2026-03-05
Pages: 131
USD 3950.00
(Single User License)
The global PRRS Vaccines market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 543 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
Published Date: 2026-03-05
Pages: 146
USD 2900.00
(Single User License)
The global PRRS Vaccines market is projected to grow from US$ 410 million in 2024 to US$ 527 million by 2031, at a CAGR of 3.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-30
Pages: 176
USD 4900.00
(Single User License)
The global market for PRRS Vaccines was estimated to be worth US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published Date: 2025-05-23
Pages: 134
USD 3950.00
(Single User License)
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 527 million by 2031, at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period.
Published Date: 2025-05-23
Pages: 175
USD 4900.00
(Single User License)
The global PRRS Vaccines market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published Date: 2025-05-23
Pages: 109
USD 4250.00
(Single User License)
The global market for PRRS Vaccines was valued at US$ 410 million in the year 2024 and is projected to reach a revised size of US$ 527 million by 2031, growing at a CAGR of 3.5% during the forecast period.
Published Date: 2025-05-23
Pages: 115
USD 2900.00
(Single User License)
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
Published Date: 2024-04-22
Pages: 117
USD 4900.00
(Single User License)
The global PRRS Vaccines market size was US$ 429 million in 2025 and is forecast to reach a readjusted size of US$ 543 million by 2032 with a CAGR of 3.5% during the forecast period 2026-2032.
Published: 2026-03-09
Pages: 104
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 543 million by 2032, at a CAGR of 3.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-09
Pages: 179
The global market for PRRS Vaccines was estimated to be worth US$ 429 million in 2025 and is projected to reach US$ 543 million, growing at a CAGR of 3.5% from 2026 to 2032.
Published: 2026-03-05
Pages: 131
The global PRRS Vaccines market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 543 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
Published: 2026-03-05
Pages: 146
The global PRRS Vaccines market is projected to grow from US$ 410 million in 2024 to US$ 527 million by 2031, at a CAGR of 3.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-30
Pages: 176
The global market for PRRS Vaccines was estimated to be worth US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published: 2025-05-23
Pages: 134
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 527 million by 2031, at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period.
Published: 2025-05-23
Pages: 175
The global PRRS Vaccines market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published: 2025-05-23
Pages: 109
The global market for PRRS Vaccines was valued at US$ 410 million in the year 2024 and is projected to reach a revised size of US$ 527 million by 2031, growing at a CAGR of 3.5% during the forecast period.
Published: 2025-05-23
Pages: 115
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
Published: 2024-04-22
Pages: 117
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now